Safety and Efficacy of Itacitinib in Adults with Systemic Sclerosis: a Phase II, Randomized, Controlled Trial
Latest Information Update: 01 Oct 2024
At a glance
- Drugs Itacitinib (Primary)
- Indications Diffuse scleroderma
- Focus Therapeutic Use
- Acronyms SCLERITA
- 06 Feb 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Oct 2022 to 2 Feb 2023.
- 06 Feb 2023 Planned End Date changed from 1 Oct 2025 to 1 Feb 2026.
- 06 Feb 2023 Planned primary completion date changed from 1 Oct 2025 to 1 Feb 2026.